Compare Bajaj Finserv Healthcare Fund vs ICICI Prudential Healthcare Fund
Bajaj Finserv Healthcare Fund
EquitySectoral-Pharma
ICICI Prudential Healthcare Fund
EquitySectoral-Pharma
Risk
Very High
Very High
Rating
-
4.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.59
2.07
NAV
₹11.47
₹45.00
Fund Started
06 Dec 2024
25 Jun 2018
Fund Size
₹405.14 Cr
₹6861.20 Cr
Exit Load
1% for redemption within 3 Months
Exit load of 1% if redeemed within 15 days.
1 Year
12.97%
2.35%
3 Year
-
20.75%
5 Year
-
14.94%
Equity
95.56%
98.91%
Cash
2.12%
1.09%
Top 10 Holdings
Name | Assets |
|---|---|
Divi's Laboratories Ltd. | 9.75% |
Sun Pharmaceutical Industries Ltd. | 8.96% |
Piramal Pharma Ltd. | 6.36% |
Rubicon Research Ltd. | 6.08% |
Aurobindo Pharma Ltd. | 6.03% |
Apollo Hospitals Enterprise Ltd. | 5.51% |
Torrent Pharmaceuticals Ltd. | 4.78% |
Emcure Pharmaceuticals Ltd. | 4.03% |
Laurus Labs Ltd. | 3.91% |
Neuland Laboratories Ltd. | 3.82% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.49% |
Dr. Reddy's Laboratories Ltd. | 9.73% |
Cipla Ltd. | 5.79% |
Biocon Ltd. | 5.33% |
Mankind Pharma Ltd. | 5.04% |
Alkem Laboratories Ltd. | 4.81% |
Medplus Health Services Ltd. | 4.31% |
Cohance Lifesciences Ltd. | 4.06% |
Divi's Laboratories Ltd. | 3.78% |
Syngene International Ltd. | 3.50% |
Name
-
-
Start Date
-
-
Description
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
06 Dec 2024
25 Jun 2018
